Dashboard
Manage Tickers

TSX:APSna


na (na)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 474.56 $ 0.00 (0 %)
DIA $ 417.12 $ -0.12 (-0.03 %)
SPY $ 563.86 $ 0.00 (0 %)
TLT $ 100.82 $ -0.49 (-0.48 %)
GLD $ 237.35 $ -1.32 (-0.55 %)
$ na
-- x --
-- x --
-- - --
na - na
0
na
na
na
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Aptose Biosciences Secures $10M Loan From ...
08/30/2024 20:31:02

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology...

Core News & Articles
Aptose Announces $4.43M Registered Direct ...
05/31/2024 12:09:55

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology...

Core News & Articles
Aptose Announces Pricing Of Underwritten O...
01/26/2024 13:04:19

SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (N...

Core News & Articles
Aptose Tuspetinib Clinical Data Featured I...
12/10/2023 13:14:42

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company develop...

Core News & Articles
Aptose Tuspetinib Clinical Data Selected F...
11/02/2023 13:10:57

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology...

Core News & Articles
Aptose Biosciences Establishes New At-The-...
12/12/2022 11:16:06

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company develop...

Core News & Articles
Aptose Announced Tuspetinib Continues to D...
12/11/2022 15:10:21

Aptose Biosciences Inc. ("Aptose") (NASDAQ: APTO, TSX: APS) today provided a clinical update of its lead oral myeloid k...

Core News & Articles
Aptose Receives Fast Track Designation For...
05/04/2022 11:36:45

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company develop...

Core News & Articles
Aptose Biosciences Announces Luxeptinib Pr...
05/02/2022 20:19:21

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology...

Core News & Articles
Aptose Biosciences Announces Its Decision ...
12/20/2021 12:38:25

Aptose Biosciences Inc. ("Aptose") (NASDAQ:APTO, TSX:APS) today announced its decision to discontinue further clinical ...

Core News & Articles
Aptose Biosciences Reports The Oral Myeloi...
12/13/2021 21:32:06

Aptose Biosciences Inc. ("Aptose") (NASDAQ:APTO, TSX:APS) today reported that the oral myeloid kinome inhibitor HM43239...

Core News & Articles
Aptose Presents For Corporate Update Event
06/11/2021 11:55:58

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing...

Core News & Articles
Aptose To Present CG-806 And APTO-253 Data...
11/04/2020 15:18:31

SAN DIEGO and TORONTO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose") (NASDAQ:APTO, TSX:APS), a c...

Core News & Articles
Cantor Fitzgerald Initiates Coverage On Ap...
10/19/2020 13:07:41

Cantor Fitzgerald analyst Alethia Young initiates coverage on Aptose Biosciences (TSX:APS) with a Overweight rating and anno...

Core News & Articles
Aptose Initiates Dosing of CG-806 in Patie...
10/19/2020 11:10:11

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differen...

Core News & Articles
Aptose Announces FDA Allowance Of IND For ...
06/29/2020 11:03:14

  Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML Phase 1a/b study in B...

Core News & Articles
Aptose Biosciences Highlights Presentation...
06/12/2020 11:01:03

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differen...

Core News & Articles
Aptose to Present Early CG-806 Clinical Fi...
05/14/2020 13:19:32

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differen...

Core News & Articles
Aptose Biosciences Establishes New At-The-...
05/05/2020 20:29:02

SAN DIEGO and TORONTO, May 05, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:A...

Core News & Articles
Aptose Highlights Presentation Of Prelim. ...
04/27/2020 13:09:18

Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that tar...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION